Upstream Bio (UPB) Competitors $11.68 +0.09 (+0.78%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$11.68 0.00 (0.00%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock UPB vs. MIRM, ARWR, AAPG, NAMS, BLTE, HRMY, KNSA, VCEL, DNLI, and CGONShould you be buying Upstream Bio stock or one of its competitors? The main competitors of Upstream Bio include Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), Ascentage Pharma Group International (AAPG), NewAmsterdam Pharma (NAMS), Belite Bio (BLTE), Harmony Biosciences (HRMY), Kiniksa Pharmaceuticals (KNSA), Vericel (VCEL), Denali Therapeutics (DNLI), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry. Upstream Bio vs. Its Competitors Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International NewAmsterdam Pharma Belite Bio Harmony Biosciences Kiniksa Pharmaceuticals Vericel Denali Therapeutics CG Oncology Mirum Pharmaceuticals (NASDAQ:MIRM) and Upstream Bio (NASDAQ:UPB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking. Do analysts prefer MIRM or UPB? Mirum Pharmaceuticals presently has a consensus target price of $60.73, indicating a potential upside of 25.31%. Upstream Bio has a consensus target price of $56.50, indicating a potential upside of 383.73%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17Upstream Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is MIRM or UPB more profitable? Upstream Bio has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -31.69%. Upstream Bio's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Mirum Pharmaceuticals-31.69% -41.22% -14.81% Upstream Bio N/A N/A N/A Does the MarketBeat Community favor MIRM or UPB? Mirum Pharmaceuticals received 132 more outperform votes than Upstream Bio when rated by MarketBeat users. However, 80.00% of users gave Upstream Bio an outperform vote while only 76.40% of users gave Mirum Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMirum PharmaceuticalsOutperform Votes13676.40% Underperform Votes4223.60% Upstream BioOutperform Votes480.00% Underperform Votes120.00% Which has better earnings & valuation, MIRM or UPB? Upstream Bio has lower revenue, but higher earnings than Mirum Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMirum Pharmaceuticals$379.25M6.33-$163.41M-$1.61-30.10Upstream Bio$2.30M273.66N/AN/AN/A Does the media prefer MIRM or UPB? In the previous week, Mirum Pharmaceuticals had 6 more articles in the media than Upstream Bio. MarketBeat recorded 9 mentions for Mirum Pharmaceuticals and 3 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 0.89 beat Mirum Pharmaceuticals' score of 0.79 indicating that Upstream Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upstream Bio 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryUpstream Bio beats Mirum Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get Upstream Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for UPB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPB vs. The Competition Export to ExcelMetricUpstream BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$628.31M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E RatioN/A8.7827.1420.06Price / Sales273.66255.64411.98157.10Price / CashN/A65.8538.2534.64Price / BookN/A6.557.064.70Net IncomeN/A$143.93M$3.23B$247.88M7 Day Performance7.85%3.84%2.85%2.63%1 Month Performance22.95%11.20%9.06%6.36%1 Year PerformanceN/A4.18%31.43%14.05% Upstream Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPBUpstream Bio1.9399 of 5 stars$11.68+0.8%$56.50+383.7%N/A$628.31M$2.30M0.0038MIRMMirum Pharmaceuticals3.8483 of 5 stars$45.97+3.4%$60.73+32.1%+85.0%$2.28B$379.25M-22.76140Analyst RevisionARWRArrowhead Pharmaceuticals3.6107 of 5 stars$16.40+2.1%$42.13+156.9%-32.1%$2.26B$545.21M-3.17400Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600NAMSNewAmsterdam Pharma2.9925 of 5 stars$18.93+4.5%$43.00+127.2%+3.2%$2.13B$47.14M-10.074Trending NewsAnalyst ForecastAnalyst RevisionBLTEBelite Bio2.2911 of 5 stars$65.02+0.2%$96.67+48.7%+25.2%$2.07BN/A-58.5810Short Interest ↑Analyst RevisionHRMYHarmony Biosciences4.7766 of 5 stars$35.56+3.1%$53.00+49.0%+18.4%$2.04B$744.85M16.85200Positive NewsShort Interest ↑Analyst RevisionKNSAKiniksa Pharmaceuticals3.2478 of 5 stars$27.92+2.0%$38.80+39.0%+61.1%$2.04B$481.17M-199.41220Trending NewsInsider TradeVCELVericel2.6777 of 5 stars$40.46-2.0%$61.14+51.1%+2.0%$2.04B$238.54M674.45300Positive NewsHigh Trading VolumeDNLIDenali Therapeutics4.3576 of 5 stars$13.96+5.4%$33.71+141.5%-29.7%$2.03B$330.53M-5.06430Positive NewsAnalyst RevisionHigh Trading VolumeCGONCG Oncology2.5187 of 5 stars$26.59+3.8%$58.22+119.0%-25.6%$2.03B$662K-17.6161Positive NewsAnalyst Revision Related Companies and Tools Related Companies MIRM Alternatives ARWR Alternatives AAPG Alternatives NAMS Alternatives BLTE Alternatives HRMY Alternatives KNSA Alternatives VCEL Alternatives DNLI Alternatives CGON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPB) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upstream Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upstream Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
